Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported fourth quarter EPS of $-0.02, $0.33 better than the analyst estimate of $-0.35. Revenue for the quarter came in at $17.57M versus the consensus estimate of $4.66M.
Aclaris Therapeutics Inc's stock price closed at $1.21. It is up 33.91% in the last 3 months and down -89.89% in the last 12 months.
Aclaris Therapeutics Inc saw 6 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Aclaris Therapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Aclaris Therapeutics Inc's Financial Health score is "fair performance".
Check out Aclaris Therapeutics Inc's recent earnings performance, and Aclaris Therapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar